```json
{
"content": [
{
"type": "paragraph",
"content": "The venous thromboembolism treatment industry trends have evolved rapidly over the past 18 months, driven by innovation and strategic collaborations. Partnerships have intensified, with major players like Bayer AG forming alliances to advance direct oral anticoagulant (DOAC) research. Mergers & acquisitions saw momentum, including Bristol-Myers Squibb’s acquisition of a biotech firm specializing in next-generation anticoagulants, enhancing its pipeline. Product launches have prioritized patient-centric solutions, such as Sanofi’s expansion into subcutaneous factor Xa inhibitors for long-term VTE management. Regulatory changes underscored the FDA’s 2023 emphasis on real-world evidence for drug approvals, while the EMA updated guidelines to prioritize safety profiles in pediatric VTE therapies. A shift in consumer trends toward outpatient care and reduced hospital readmissions has driven demand for home-monitoring technologies. Notably, funding rounds in 2024–2025 saw $120M raised by digital health startups developing AI-powered thrombosis risk assessment tools, reflecting the industry’s pivot toward preventive and personalized care models."
},
{
"type": "list",
"title": "Key Developments",
"items": [
{ "text": "Bristol-Myers Squibb acquired a biotech firm for $3.2B to expand its anticoagulant portfolio", "level": 1 },
{ "text": "Sanofi launched a subcutaneous factor Xa inhibitor in Q2 2024, targeting long-term VTE therapy", "level": 1 },
{ "text": "FDA and EMA introduced updated regulatory frameworks emphasizing real-world data and pediatric safety", "level": 1 },
{ "text": "Digital health startups secured $120M in funding for AI-driven thrombosis monitoring tools", "level": 1 }
]
}
]
}
```
